Analysis of differences between indication and prescription of gastroprotection in patients with risk factors treated with nonsteroidal anti-inflammatory agents: The GAP study;Análisis de las diferencias entre indicación y prescripción de gastroprotección en pacientes con factores de riesgo tratados con antiinflamatorios no esteroideos: estudio GAP

Gastroenterologia y Hepatologia

Volumn 33, Issue 2, 2010, Pages 80-91

  Lanas, Angel ^a   Muñoz, Maria ^a   Caballero Correa, Maria ^b   Martínez Jiménez, Pedro ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b Departamento Médico Janssen Cilag   (Spain)

Author keywords

Gastrointestinal risk factors; Gastroprotection; Misoprostol; Nonsteroidal anti inflammatory drugs; Proton pump inhibitors

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG INDICATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; MEDICAL SPECIALIST; PRESCRIPTION; RISK FACTOR; SPAIN; STOMACH PROTECTION; TREATMENT DURATION;

AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; GASTROINTESTINAL DISEASES; HUMANS; MEDICINE; MIDDLE AGED; MISOPROSTOL; PALLIATIVE CARE; PROTON PUMP INHIBITORS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 74249111728     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2009.09.009     Document Type: Article

References (27)

1. Phillips A.C., Polisson R.P., and Simon L.S. NSAIDs and the elderly. Toxicity and economic implications. Drugs Aging 10 (2007) 119-130
2. Pincus T., Koch G., Lei H., Mangal B., Sokka T., Moskowitz R., et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): Two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. An Rheum Dis 63 (2004) 931-939
3. Case J.P., Baliunas A.J., and Block J.A. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: A randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 163 (2003) 169-178
4. Watson M., Brookes S.T., Faulkner A., and Kirwan J. WITHDRAWN: Non-aspirin, non-steroidal anti-inflammatory drugs for treating osteoarthritis of the knee. Cochrane Database Syst Rev (2007) CD000142
5. Soll A.H., Weinstein W.M., Kurata J., and McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 114 (1991) 307-319
6. Scheiman J.M. NSAID-induced peptic ulcer disease: A critical review of pathogenesis and management. Dig Dis 12 (1994) 210-222
7. Lanas A. Non-steroidal anti-inflammatory drugs and gastrointestinal bleeding. Ital J Gastroenterol Hepatol 31 (1993) S37-S42
8. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs-nice or necessary?. Rev Gastroenterol Dis 4 (2004) S33-S41
9. Singh G., and Rosen Ramey D. NSAID induced gastrointestinal complications: The ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 25 (1998) 8-16
10. Lanas A., Perez-Aisa M.A., Feu F., Ponce J., Saperas E., Santolaria S., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 100 (2005) 1685-1693
11. Wilcox C.M., Allison J., Benzul K., Borum M., Cryer B., Grosser T., et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 4 (2006) 1082-1089
12. Lanza F.L. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 93 (1998) 2037-2046
13. Hunt R.H., Barkun A.N., Baron D., Bombardier C., Bursey F.R., Marshall J.R., et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: Defining the role of gastroprotective agents. Can J Gastroenterol 16 (2002) 231-240
14. Dubois R.W., Melmed G.Y., Henning J.M., and Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Drug Saf 27 (2004) 411-420
15. Sturkenboom M.C., Burke T.A., Dieleman J.P., Tangelder M.J., Lee F., and Goldstein J.L. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 42 (2003) iii23-iii31
16. Carvajal A., Martín Arias L.H., Vega E., García Sánchez J.A., Martín Rodríguez I., Pilar García Ortega1 P., et al. Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study. Eur J Clin Pharmacol 60 (2004) 439-444
17. Lanas A. Update on gastrointestinal disorders associated with non-steroidal anti-inflammatory drugs. Gastroenterol Hepatol 31 (2008) 35-41
18. Abraham N.S., El-Serag H.B., Johnson M.L., Hartman C., Richardson P., Ray W.A., et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 129 (2005) 1171-1178
19. Schnitzer T.J., Kong S.X., Mavros P.P., Straus W.L., and Watson D.J. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: Analysis of a large United States claims database. Clin Ther 23 (2001) 1984-1998
20. Nardulli G., and Lanas A. Risk of gastrointestinal bleeding with aspirin and platelet antiaggregants. Gastroenterol Hepatol 32 (2009) 36-43
21. Lanas A., Martin-Mola E., Ponce J., Navarro F., Pique J.M., and Blanco F.J. Estrategias para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos. Recomendaciones de la Asociación Española de Gastroenterología y de la Sociedad Española de Reumatología. Gastroenterol Hepatol 26 (2003) 485-502
22. Lanas A., Bajador E., Serrano P., Fuentes J., Carreño S., Guardia J., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000) 834-839
23. Hartnell N.R., Flanagan P.S., MacKinnon N.J., and Bakowsky V.S. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada. Am J Geriatr Pharmacother 2 (2004) 171-180
24. Herings R.M., and Goettsch W.G. Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmacother 38 (2004) 760-763
25. Helin-Salmivaara A., Huupponen R., Virtanen A., Lammela J., and Klaukka T. Frequent prescribing of drugs with potential gastrointestinal toxicity among continuous users of non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 61 (2005) 425-431
26. Lanas A, Esplugues JV, Zapardiel J, Sobreviela E. An education-based approach to addressing non-evidence-based clinical practice among specialists in the prevention of NSAID-associated GI complications. World J Gastroenterology. 2009 (in press)
27. Casado R., Polo-Tomas M., Del Rio A.M., Scheiman J., and Lanas A. Prescription rates of PPI therapy are high in patients on dual antiplatelet therapy in Spain, regardless of the presence of risk factors. Gastroenterology 136 (2009) 409